184 related articles for article (PubMed ID: 29054984)
1. Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol.
Pearson HE; Iida M; Orbuch RA; McDaniel NK; Nickel KP; Kimple RJ; Arbiser JL; Wheeler DL
Mol Cancer Ther; 2018 Jan; 17(1):204-214. PubMed ID: 29054984
[TBL] [Abstract][Full Text] [Related]
2. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
Iida M; Bahrar H; Brand TM; Pearson HE; Coan JP; Orbuch RA; Flanigan BG; Swick AD; Prabakaran PJ; Lantto J; Horak ID; Kragh M; Salgia R; Kimple RJ; Wheeler DL
Mol Cancer Ther; 2016 Sep; 15(9):2175-86. PubMed ID: 27422810
[TBL] [Abstract][Full Text] [Related]
3. Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs.
Prasad R; Katiyar SK
Adv Exp Med Biol; 2016; 928():245-265. PubMed ID: 27671820
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of the bisphenolic honokiol from Magnolia officinalis against multiple drug-resistant tumor cells as determined by pharmacogenomics and molecular docking.
Saeed M; Kuete V; Kadioglu O; Börtzler J; Khalid H; Greten HJ; Efferth T
Phytomedicine; 2014 Oct; 21(12):1525-33. PubMed ID: 25442261
[TBL] [Abstract][Full Text] [Related]
5. Discovery and synthesis of novel magnolol derivatives with potent anticancer activity in non-small cell lung cancer.
Tang H; Zhang Y; Li D; Fu S; Tang M; Wan L; Chen K; Liu Z; Xue L; Peng A; Ye H; Chen L
Eur J Med Chem; 2018 Aug; 156():190-205. PubMed ID: 30006164
[TBL] [Abstract][Full Text] [Related]
6. Honokiol, a multifunctional tumor cell death inducer.
Tian W; Xu D; Deng YC
Pharmazie; 2012 Oct; 67(10):811-6. PubMed ID: 23136712
[TBL] [Abstract][Full Text] [Related]
7. Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor.
Singh T; Gupta NA; Xu S; Prasad R; Velu SE; Katiyar SK
Oncotarget; 2015 Aug; 6(25):21268-82. PubMed ID: 26020804
[TBL] [Abstract][Full Text] [Related]
8. Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo.
Bonner MY; Karlsson I; Rodolfo M; Arnold RS; Vergani E; Arbiser JL
Oncotarget; 2016 Mar; 7(11):12857-68. PubMed ID: 26871475
[TBL] [Abstract][Full Text] [Related]
9. Honokiol analogs: a novel class of anticancer agents targeting cell signaling pathways and other bioactivities.
Kumar A; Kumar Singh U; Chaudhary A
Future Med Chem; 2013 May; 5(7):809-29. PubMed ID: 23651094
[TBL] [Abstract][Full Text] [Related]
10. Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets.
Banik K; Ranaware AM; Deshpande V; Nalawade SP; Padmavathi G; Bordoloi D; Sailo BL; Shanmugam MK; Fan L; Arfuso F; Sethi G; Kunnumakkara AB
Pharmacol Res; 2019 Jun; 144():192-209. PubMed ID: 31002949
[TBL] [Abstract][Full Text] [Related]
11. Honokiol inhibits in vitro and in vivo growth of oral squamous cell carcinoma through induction of apoptosis, cell cycle arrest and autophagy.
Huang KJ; Kuo CH; Chen SH; Lin CY; Lee YR
J Cell Mol Med; 2018 Mar; 22(3):1894-1908. PubMed ID: 29363886
[TBL] [Abstract][Full Text] [Related]
12. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
13. Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors.
Song JM; Anandharaj A; Upadhyaya P; Kirtane AR; Kim JH; Hong KH; Panyam J; Kassie F
Oncotarget; 2016 Sep; 7(36):57752-57769. PubMed ID: 27458163
[TBL] [Abstract][Full Text] [Related]
14. Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells.
Lee B; Kim CH; Moon SK
FEBS Lett; 2006 Oct; 580(22):5177-84. PubMed ID: 16962592
[TBL] [Abstract][Full Text] [Related]
15. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells.
Shigemura K; Arbiser JL; Sun SY; Zayzafoon M; Johnstone PA; Fujisawa M; Gotoh A; Weksler B; Zhau HE; Chung LW
Cancer; 2007 Apr; 109(7):1279-89. PubMed ID: 17326044
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
17. Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells.
Kaushik G; Ramalingam S; Subramaniam D; Rangarajan P; Protti P; Rammamoorthy P; Anant S; Mammen JM
Am J Surg; 2012 Dec; 204(6):868-73. PubMed ID: 23231930
[TBL] [Abstract][Full Text] [Related]
18. Honokiol: a novel natural agent for cancer prevention and therapy.
Arora S; Singh S; Piazza GA; Contreras CM; Panyam J; Singh AP
Curr Mol Med; 2012 Dec; 12(10):1244-52. PubMed ID: 22834827
[TBL] [Abstract][Full Text] [Related]
19. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
20. Honokiol, a potential therapeutic agent, induces cell cycle arrest and program cell death in vitro and in vivo in human thyroid cancer cells.
Lu CH; Chen SH; Chang YS; Liu YW; Wu JY; Lim YP; Yu HI; Lee YR
Pharmacol Res; 2017 Jan; 115():288-298. PubMed ID: 27940017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
